Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 14 at 2:00 PM ET

Register Free →

Search

Top

GENENTECH INC

Subsidiary ofROCHE HOLDING AGUEI: F7F8GZXL7Q93CAGE: 1HZ12

GENENTECH INC is a federal contractor, registered under UEI F7F8GZXL7Q93 and CAGE code 1HZ12. It has been awarded $262,099,740 in federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology), Pharmaceutical Preparation Manufacturing, and Other NAICS codes (3 codes, <0.5% each). Top awarding agencies include Department Of Health And Human Services, Department Of Veterans Affairs, and Other agencies (1 agencies, <0.5% each).

Contact Information

Registration and classification details

Phone+1 (555) 000-0000

Websitewww.gene.com

Address123 Main St, City, ST 12345

Registration

UEI Code

F7F8GZXL7Q93

CAGE Code

1HZ12

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationForeign OwnedManufacturer of Goods

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Genentech Inc. specializes in biotechnology research and development, focusing on the discovery and advancement of novel therapeutic modalities through scientific innovation. Their core capabilities include molecular biology, protein engineering, and preclinical development of biologics, with deep e...

Key Performance Metrics

Awards Count

50

All time

Active

1

Currently performing

Completed

49

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$253.3M96.7%Department Of Veterans Affairs$8.7M3.3%

Other agencies (1 agencies, <0.5% each)$44.9K0%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$252.8M96.5%325412 - Pharmaceutical Preparation Manufacturing$8.7M3.3%

Others - Other NAICS codes (3 codes, <0.5% each)$627.4K0.2%

Awards by Agency Over Time

Awards by Place of Performance

Compete with GENENTECH INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for GENENTECH INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in GENENTECH INC's top NAICS codes and agencies

Therapeutic Development for Drug-Resistant Infectious DiseasesThis subcontract focuses on the development of therapeutic candidates designed to treat drug-resistant infectious diseases in support of prime contractors for the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. The scope of work encompasses the identification and synthesis of candidates, efficacy testing against resistant strains, and comprehensive safety profiling and toxicity testing. To successfully execute these tasks, the provider must possess specialized chemical synthesis equipment, antimicrobial susceptibility testing capabilities, and the necessary biosafety certifications. The primary deliverables for this engagement include validated therapeutic candidates, detailed safety and efficacy data, and strategic maturation plans. This opportunity is categorized under NAICS code 325412 and is associated with the Department of Health and Human Services. Interested parties should note the response deadline of December 8, 2026.

National Institutes Of Health Niaid

POSTED

DEADLINE

in about 2 months

High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.

National Institutes Of Health

POSTED

DEADLINE

Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.

National Institutes Of Health

POSTED

DEADLINE

Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

Solicitation # RFA-RM-27-007

The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)

Solicitation # RFA-HG-27-008

The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.

National Institutes Of Health

POSTED

DEADLINE

Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-RM-27-016

The National Institutes of Health (NIH) is soliciting applications under RFA-RM-27-016 to establish SenNet Discovery and Validation Centers (DVCs) as part of Stage 2 of the Cellular Senescence Network. The primary objective of these centers is to define, refine, and validate tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. DVCs are required to investigate the functional consequences of these signatures in human health and disease, generate high-quality molecular, cellular, and spatial datasets for public release via the Data Coordination and Informatics Center, and execute consortium-wide organizational and outreach activities. The maximum project period is five years, with application budgets limited to approximately 3 million dollars in direct costs per year. A specific requirement includes a mandatory 600,000 dollar annual direct cost allocation for the SenNet Organization and Outreach Component, of which 40 to 45 percent must support educational programs. Additionally, starting in Year 2, centers must set aside approximately 10 percent of their total budget for cross-consortium validation. Applications are evaluated through the NIH peer review system based on significance, approach, and the protection of human subjects, with performance measured annually by the successful acceptance and public release of data. Applicants must maintain active registrations in the System for Award Management and eRA Commons. Required submission materials include a 30-page application divided into four elements covering vision, preclinical modeling, biospecimen management, and outreach, along with letters of support and human subjects documentation where applicable. Awardees must adhere to strict data security protocols, including a seven-year confidentiality disclosure agreement and a requirement to report cybersecurity incidents within 48 hours.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-007

The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications under RFA-HG-27-007 to establish centers for the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to characterize genomic variation and assess how individual variants in DNA, RNA, or protein-coding elements impact genome function and phenotypes. Funded centers will utilize high-throughput methods to perturb variants, collect molecular and cellular data, and develop portable data processing pipelines. These centers are expected to collaborate within the consortium to coordinate assays and cell types, contributing raw and processed data to the IGVF Catalog via the Data Analysis and Coordination Center. The funding cycle runs from 2027 through fiscal year 2031, with a maximum project period of five years and budgets limited to 2 million dollars in direct costs per year. Notably, 20 percent of direct costs must be allocated to support collaborative work. Applications are evaluated based on scientific merit through the NIH peer review system and a second level of review by the National Advisory Council for Human Genome Research, focusing on significance, overall impact, and the utility of the proposed assays. Clinical trials are not allowed, and research involving human subjects must comply with 45 CFR Part 46. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required submissions include a Research Strategy limited to 30 pages, a Resource Sharing Plan, and a Data Management and Sharing Plan. Key personnel requirements include a minimum of three person-months of effort for the PD/PI and a dedicated Project Manager committing at least four person-months. Additionally, awardees must implement a cybersecurity incident response plan with a 48-hour notification requirement for any discovered incidents.

National Institutes Of Health

POSTED

DEADLINE

Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-009

Solicitation RFA-HG-27-009 is a Notice of Funding Opportunity from the National Institutes of Health, under the Department of Health and Human Services, for a UM1 Research Project with Complex Structure Cooperative Agreement. The program seeks to establish interaction centers to study how genetic or environmental interactions modify genomic variant impact as part of the second phase of the Impact of Genomic Variation on Function (IGVF) Consortium. Awardees must develop a quantitative research framework to detect joint effects beyond additive modifiers, apply genomic perturbation methods to collect phenotypic data, and share all resulting data, analyses, and predictive methods through the IGVF portal and catalog. The initiative is designed as discovery science to improve the understanding of genome-wide association studies and polygenic scores. Eligible applicants include small businesses and other for-profit organizations, with a maximum project period of five years and a budget limit of 1.5 million dollars in direct costs per year. Applications are due by December 14, 2026, and are evaluated via the NIH peer review system based on significance, contribution to consortium goals, and the rigor of the proposed research. Key requirements include a dedicated Project Manager devoting at least four person months and a PD/PI effort of at least three person months. Additionally, awardees must comply with strict cybersecurity incident reporting guidelines, maintain active SAM and eRA Commons registrations, and adhere to federal regulations regarding human subjects and vertebrate animal research.

National Institutes Of Health

POSTED

DEADLINE

Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)

Solicitation # RFA-HG-27-010

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications through RFA-HG-27-010 for the Computational Modeling and Analysis of the Impact of Genomic Variation on Function initiative. This UM1 Research Project with Complex Structure Cooperative Agreement seeks to establish centers that will join the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to develop, apply, and test interpretable computational models that utilize biological, biochemical, and biophysical mechanistic information to determine how genomic variation affects genome function and phenotypes related to human health. Awardees are expected to produce open-source software, models, and documentation, while sharing predictions and integrative analyses via the IGVF catalog and data portal. The maximum project period is five years, with application budgets limited to 800,000 dollars in direct costs. A critical requirement is that 20 percent of direct costs must be allocated annually to support collaborative work. Personnel requirements include a minimum aggregate effort of three person months for PD/PIs and a dedicated Project Manager devoting at least four person months. Applications are evaluated via the NIH peer review system based on significance, investigators, innovation, approach, and environment, with a focus on the likelihood of exerting a sustained influence on the research field. Eligible applicants include small businesses and other for-profit organizations, provided they maintain active SAM registration and a Unique Entity Identifier. All awards are administered under 42 CFR Part 52 and 2 CFR Part 200.

National Institutes Of Health

POSTED

DEADLINE

Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-RM-27-016

The National Institutes of Health is seeking applications for the Cellular Senescence Network Discovery and Validation Centers under solicitation RFA-RM-27-016. This initiative represents Stage 2 of the SenNet program, focusing on the definition, refinement, and validation of tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. Selected centers will investigate the functional consequences of these signatures on human health and disease while generating high-quality molecular, cellular, and spatial datasets to be shared with the broader scientific community. Awardees are expected to utilize complementary experimental systems to validate biomarkers and analyze responses to senotherapeutic approaches or senescence-associated perturbations. In addition to research goals, applicants must propose specific aims for consortium-wide organizational and outreach activities. Interested parties must submit their responses by the deadline of November 24, 2026.

POSTED

DEADLINE

in about 1 month

Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

Solicitation # RFA-RM-27-007

The National Institutes of Health is soliciting proposals for the Cellular Senescence Network through solicitation RFA-RM-27-007 to develop or adapt innovative senescence technologies. These technologies aim to identify, characterize, and understand the biological consequences of senescent cell heterogeneity within tissue environments and secretomes. The ultimate goal is to create novel strategies for modulating these cells in vivo and predicting outcomes for human aging and various disease conditions. These five-year, milestone-driven awards are structured in two distinct phases. The initial two-year UG3 phase focuses on technology development and feasibility, while the subsequent three-year UH3 phase is dedicated to optimization, refinement, and validation, concluding with a collaborative demonstration project within SenNet. Applicants must submit both phases together, though transition to the UH3 phase is contingent upon an administrative review following the second year. Responses are due by November 24, 2026.

POSTED

DEADLINE

in about 1 month

IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)

Solicitation # RFA-HG-27-008

The National Human Genome Research Institute is seeking applications for the Impact of Genomic Variation on Function Data and Coordinating Center under solicitation RFA-HG-27-008. The selected center will act as the primary coordinating hub for the IGVF Consortium, focusing on the development and expansion of accessible resources such as a data portal and a searchable catalog of predicted and measured variant impacts. Key responsibilities include facilitating consortium activities, collaborating with other research programs, and gathering community input to refine the catalog's design to accelerate the understanding of genomic variation. This federal solicitation was posted on October 9, 2026, with a response deadline of December 15, 2026. The opportunity is designated as a U24 grant, and clinical trials are not allowed. The project aims to maximize the overall scientific impact of the IGVF Consortium through strategic coordination and the provision of comprehensive genomic data resources.

National Human Genome Research Institute

POSTED

DEADLINE

Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-009

The National Human Genome Research Institute, under the National Institutes of Health, is soliciting applications for solicitation RFA-HG-27-009 to establish interaction centers focused on studying how genetic and environmental interactions influence genomic variant impact. Selected centers are required to develop a research framework to investigate non-additive modifiers, experimentally test variant combinations, and share their findings, data, and predictive methodologies through the Impact of Genomic Variation on Function portal and catalog. This initiative aims to improve the prediction of critical interactions, enhance the understanding of genome-wide association studies, and refine polygenic scores. As members of the IGVF Consortium, participating centers must collaborate to ensure resources remain accessible and coordinate on assays, variants, and cell types to develop unified analysis strategies. Interested parties must submit their applications by the response deadline of December 15, 2026. This federal opportunity emphasizes a combination of original research and resource development to map the interaction landscape of genomic variation.

National Human Genome Research Institute

POSTED

DEADLINE

Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-007

The National Human Genome Research Institute, under the National Institutes of Health, is soliciting applications through solicitation RFA-HG-27-007 to characterize genomic variation and assess how individual variants impact genome function. The initiative focuses on systematically perturbing variants using high-throughput methods to collect data on the effects of DNA, RNA, or protein-coding elements on various phenotypes. Additionally, selected participants must develop portable and reproducible data processing pipelines to support these findings. Awarded centers will join the Impact of Genomic Variation on Function Consortium, requiring them to collaborate on assays, cell types, and analysis strategies to ensure resources are accessible to a broad user base. Interested parties must submit their responses by December 15, 2026. It is important to note that clinical trials are not allowed under this specific funding opportunity.

National Human Genome Research Institute

POSTED

DEADLINE

Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)

Solicitation # RFA-HG-27-010

The National Human Genome Research Institute, under the National Institutes of Health, is soliciting applications for the Computational Modeling and Analysis of the Impact of Genomic Variation on Function initiative. This opportunity, identified by solicitation number RFA-HG-27-010, seeks to establish centers that will develop, apply, and test predictive models and perform integrative analyses to understand how genomic variation affects genome function. Clinical trials are not permitted under this specific funding opportunity. Selected centers will join the Impact of Genomic Variation on Function Consortium, where they will collaborate to ensure resources are accessible to a broad user base. Members are expected to work with other consortium components to optimize experimental design, provide specialized analytical expertise, and execute shared analysis strategies to achieve overall consortium goals. Applications must be submitted by the response deadline of December 15, 2026.

National Human Genome Research Institute

POSTED

DEADLINE

SPF 50 Topical Sunscreen Preparation (NSN 6505-01-657-9247)This subcontract involves the supply of finished over-the-counter SPF 50 topical sunscreen for prime contractors supporting Department of Defense Medical Supply Chain projects. The required formula must be hypoallergenic, oil-free, PABA-free, and biodegradable, specifically containing 4.5 percent titanium dioxide and 4 percent zinc oxide. All products must be packaged in 3-ounce tubes in accordance with Medical Marking Standard No. 1 and ASTM D3951, with final delivery consisting of 24-tube packages shipped FOB Destination. The contract mandates strict compliance with the Buy American Act and the Berry Amendment. Identified by NSN 6505-01-657-9247 and NAICS code 325412, the project is managed under the Medical Supply Chain Pharm FSA. The place of performance is designated as FPO 96671-4077, with a response deadline set for October 14, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Manufacturer of Sterile Elastic Knuckle Fabric BandagesThis subcontract involves the manufacture of sterile, elastic knuckle fabric adhesive bandages for prime contractors supporting the Department of Defense Medical Supply Chain. The required bandages must measure 1.5 by 3 inches, utilizing rayon woven web material and latex-free adhesives. All products must undergo sterilization and labeling in accordance with Medical Marking Standard No. 1 and be delivered in cases of 1,200 units with a guaranteed shelf life of 60 months. Compliance with the Berry Amendment and the Buy American Act is mandatory for this contract. The project falls under NAICS code 325412 and is managed by the Medical Supply Chain MD Surg FSF. Interested parties should note the performance location is listed as FPO 96671-4077.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE